(AOF) – Theradiag published a turnover of 6.7 million euros in the first half, up 6.8%. “Growth accelerated slightly during the second quarter of 2023 thanks to good commercial performances in Theradiag’s two businesses: +9.4% for Theranostics and +5.3% for In Vitro Diagnostics (IVD)” , explains the biotherapy monitoring specialist. As of June 30, 2023, Theradiag’s net available cash amounted to €5.7 million compared to €6.4 million as of December 31, 2022.
The group stresses that its level is higher than the roadmap of the company.
Simon Davière, Chief Executive Officer of Theradiag commented: “The deliberate slowdown in the United States is offset by market share gains in new countries, mainly the large European markets. Backed by a comfortable level of cash, we expect in the coming months continue to develop and accelerate the commercialization of our high-margin in-house manufactured products.”
Christian Policard, Chairman of Theradiag’s Board of Directors continues: “In addition to its good commercial momentum, Theradiag has worked in recent months to deepen the collaboration with its shareholder and partner Biosynex. If synergies at the level of purchases are already in place, commercial synergies will have to be operational in the coming semesters in order to improve the performance of both companies.”